Karen J. Wernli, PhD

Wernli_Karen__205x293.jpg

“I consider patients the core of my research.”

Karen J. Wernli, PhD

Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute
Professor, Department of Health System Science, Kaiser Permanente Bernard J. Tyson School of Medicine
Affiliate Professor, Department of Epidemiology and Department of Health Systems and Population Health, University of Washington

Karen.J.Wernli@kp.org
206-287-2934
Twitter: @wernlikarenj

Biography

Karen Wernli, PhD, is a cancer epidemiologist and health services researcher whose work focuses on incorporating patient-centered outcomes to improve cancer care along the cancer care continuum, from prevention to survivorship. Her works spans several types of cancer, including lung, breast, and colorectal, and also explores the impact of cancer in special populations, such as adolescents and young adults. Her research strives to answer critical questions at the confluence of patients’ needs and clinical priorities. Overall, her research has resulted in approximately $30 million in research funding as principal investigator (PI) or site PI, more than 125 peer-reviewed publications (h-index 35), and more than 85 presentations at national conferences, symposia, and other public venues.

Dr. Wernli is a leader in multilevel intervention studies to improve lung cancer screening. She is currently conducting a pragmatic clinical trial funded by the National Cancer Institute (NCI) to test 2 multilevel interventions to improve adherence to annual lung cancer screening at Kaiser Permanente Washington (R01CA262015). Study interventions were developed using a mixed-methods approach — including patient and stakeholder engagement and human-centered design methods — to determine gaps for interventions, relevant features of interventions, and design concepts. Further, Dr. Wernli is also leading a pilot grant from the Alliance for Clinical Trials in Oncology to develop interventions to improve timely follow-up after a positive lung cancer screening scan. She is cancer care delivery research lead for the Kaiser Permanente Washington NCI Community Oncology Research Program (NCORP).

Dr. Wernli is a leader in the use of breast imaging in women with prior breast cancer, including in the use of breast magnetic resonance imaging (MRI). Dr. Wernli recently completed a Patient-Centered Outcomes Research Institute (PCORI) project that compared breast MRI to mammography for women already treated for breast cancer. Called Surveillance Imaging Modalities for Breast Cancer Assessment (SIMBA), the study used data from the Breast Cancer Surveillance Consortium (BCSC) and engaged patients and stakeholders to determine the best information for patient and physician decision-making. Dr. Wernli’s team translated that information into a new decision aid for breast cancer survivors. PCORI has recognized this work nationally and pointed to SIMBA as a model for effective patient engagement.

Dr. Wernli’s other breast cancer projects include collaborating with Natasha Stout, PhD, from Harvard University on an NCI-funded study to examine trends and outcomes related to the mandatory notification of breast density that has been enacted in many states. She also led research to determine temporal trends in the use of breast MRI over 10 years, based on indication for the scans. The analysis relied on national claims-based data across all 50 states.

Dr. Wernli is leading patient-centered research in adolescent and young adult (AYA) populations. She is a project co-lead with Kaiser Permanente Southern California researcher Erin Hahn, PhD, MPH, and Veterans Affairs researcher Neetu Chawla, PhD, MPH, in an NCI-funded project to evaluate health service utilization in early survivorship for AYA populations. The research is intended to identify multilevel gaps in health care utilization in AYA early-cancer survivors for forthcoming interventions. Previously, Dr. Wernli launched the Clare Project with KPWHRI researchers, including Marlaine Figueroa Gray, PhD, to understand patient, caregiver, and provider perspectives regarding medical decision-making for patients with advanced cancer. Using novel methods, all perspectives were garnered through social media recruitment. With NCI-funding, she has evaluated temporal trends and regional variation in end-of-life care in AYA cancer populations using national claims-based data.

Finally, Dr. Wernli is expanding her research expertise in clinical research studies beyond oncology clinical trials. She is principal investigator of a multisite study of flu and COVID-19 vaccine effectiveness funded by the Centers for Disease Control and Prevention from 2022 to 2027. Her study team is annually enrolling about 1,200 participants with flu-like symptoms into her research.

Dr. Wernli is a member of the American Society for Preventive Oncology, the Society for Epidemiologic Research, the American Society for Clinical Oncology, and the American Association for Cancer Research. She is an affiliate professor of epidemiology and health systems and population health at the University of Washington and a professor of health system science at the Kaiser Permanente Bernard J. Tyson School of Medicine.

Research interests and experience

  • Cancer

    Breast, lung, colorectal, ovarian, skin, and endometrial cancer; screening and surveillance; survivorship; patient-centered care; biostatistics; low-dose CT (LDCT); mammography; surveillance imaging; breast magnetic resonance imaging (MRI); systematic reviews; multilevel intervention studies; pragmatic clinical trials

  • Health Services & Economics

    Comparative effectiveness research, health outcomes research, patient-centered outcomes, health care quality, implementation science

    Preventive Medicine

    Cancer screening and surveillance

  • Patient-Centeredness

    Patient engagement, stakeholder engagement, qualitative research methods, mixed-methods, human-centered design

  • Vaccines & Infectious Diseases

  • Aging & Geriatrics

Recent publications

Carter-Bawa L, Slaven JE Jr, Monahan PO, Brandzel S, Gao H, Wernli KJ, Lafata JE, Rawl SM. Unpacking the relationship between shared decision-making and decisional quality, decision to screen, and screening completion in lung cancer screening.  Patient Educ Couns. 2024;122:108143. doi: 10.1016/j.pec.2024.108143. Epub 2024 Jan 11.  PubMed

Bi Q, Dickerman BA, Nguyen HQ, Martin ET, Gaglani M, Wernli KJ, Balasubramani GK, Flannery B, Lipsitch M, Cobey S. Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection. LID - jiae220 [pii] LID - 10.1093/infdis/jiae220 [doi]  J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093/infdis/jiae220 [Epub ahead of print] PubMed

Wernli KJ, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman AB, Casperson M, Kirchhoff AC, Zebrack BJ, Keegan THM, Kushi L, Baggett C, Kaddas HK, Ruddy KJ, Sauder CAM, Wun T, Figueroa Gray M, Chubak J, Nichols H, Hahn EE. Emergency Department Use in Adolescent and Young Adult Cancer Early Survivors from 2006 to 2020. LID - 10.1089/jayao.2023.0174 [doi]  J Adolesc Young Adult Oncol. 2024 Apr 29. doi: 10.1089/jayao.2023.0174 [Epub ahead of print] PubMed

Smith RE, Sprague BL, Henderson LM, Kerlikowske K, Miglioretti DL, Wernli KJ, Onega T, diFlorio-Alexander RM, Tosteson ANA. Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.  Breast Cancer Res. 2024;26(1):73. doi: 10.1186/s13058-024-01820-x.  PubMed

Haas CB, Chen H, Harrison T, Fan S, Gago-Dominguez M, Castelao JE, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Easton DF, Antoniou AC, Hall P, Czene K, Andrulis IL, Mulligan AM, Milne RL, Fasching PA, Haeberle L, Garcia-Closas M, Ahearn T, Gierach GL, Haiman C, Maskarinec G, Couch FJ, Olson JE, John EM, Chenevix-Trench G, de Gonzalez AB, Jones M, Stone J, Murphy R, Aronson KJ, Wernli KJ, Hsu L, Vachon C, Tamimi RM, Lindström S. Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization. Breast Cancer Res Treat. 2024 Apr 24. doi: 10.1007/s10549-024-07306-w. Online ahead of print. PubMed

Luce C, Palazzo L, Anderson ML, Carter-Bawa L, Gao H, Green BB, Ralston JD, Rogers K, Su YR, Tuzzio L, Triplette M, Wernli KJ. A pragmatic randomized clinical trial of multilevel interventions to improve adherence to lung cancer screening (The Larch Study): Study protocol.  Contemp Clin Trials. 2024 Mar 11;140:107495. doi: 10.1016/j.cct.2024.107495 [Epub ahead of print] PubMed

Hubbard RA, Su YR, Bowles EJ, Ichikawa L, Kerlikowske K, Lowry KP, Miglioretti DL, Tosteson ANA, Wernli KJ, Lee JM. Predicting five-year interval second breast cancer risk in women with prior breast cancer. LID - djae063 [pii] LID - 10.1093/jnci/djae063 [doi]  J Natl Cancer Inst. 2024 Mar 11:djae063. doi: 10.1093/jnci/djae063 [Epub ahead of print] PubMed

Head M, Cohn B, Wernli KJ, Palazzo L, Ehrlich K, Matson A, Knerr S. Young women's perspectives on being screened for hereditary breast and ovarian cancer risk during routine primary care. Womens Health Issues. 2024 Mar 5:S1049-3867(24)00004-5. doi: 10.1016/j.whi.2024.01.004. PubMed

Frutos AM, Price AM, Harker E, Reeves EL, Ahmad HM, Murugan V, Martin ET, House S, Saade EA, Zimmerman RK, Gaglani M, Wernli KJ, Walter EB, Michaels MG, Staat MA, Weinberg GA, Selvarangan R, Boom JA, Klein EJ, Halasa NB, Ginde AA, Gibbs KW, Zhu Y, Self WH, Tartof SY, Klein NP, Dascomb K, DeSilva MB, Weber ZA, Yang DH, Ball SW, Surie D, DeCuir J, Dawood FS, Moline HL, Toepfer AP, Clopper BR, Link-Gelles R, Payne AB, Chung JR, Flannery B, Lewis NM, Olson SM, Adams K, Tenforde MW, Garg S, Grohskopf LA, Reed C, Ellington S; CDC Influenza Vaccine Effectiveness Collaborators. Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024;73(8):168-174. doi: 10.15585/mmwr.mm7308a3.  PubMed

Sumner KM, Yadav R, Noble EK, Sandford R, Joshi D, Tartof SY, Wernli KJ, Martin ET, Gaglani M, Zimmerman RK, Talbot HK, Grijalva CG, Belongia EA, Chung JR, Rogier E, Coughlin MM, Flannery B. Anti-SARS-CoV-2 antibody levels associated with COVID-19 protection in outpatients tested for SARS-CoV-2, US Flu VE Network, October 2021-June 2022. J Infect Dis. 2024 Feb 23:jiae090. doi: 10.1093/infdis/jiae090. [Epub ahead of print]. PubMed

 

News

2023_Mentorship_Awards_K.Wernli-C.Allen_1col.jpg

2023 KPWHRI mentorship awards go to Claire Allen and Karen Wernli

Kudos emphasized dedication to helping coworkers grow, providing opportunities.

Research

EDU_Dr-patient_1col.jpg

Study sheds light on needs of young people with cancer

Understanding emergency department use among adolescent and young adult cancer survivors can help address care gaps.

Research

FluVE_story_image_1col.jpg

KPWHRI contributes to flu vaccine effectiveness results

Interim data for the 2023-2024 flu season shows that the vaccine has protected all age groups.

Research

Cancer-prevention-story_1col.jpg

Improving cancer prevention and early detection

How KPWHRI is contributing to better cancer screening and better outcomes for patients.

News

Flu-VE-study_1col.jpg

KPWHRI begins new phase of flu surveillance

KPWHRI receives $10 million to continue vaccine effectiveness research for flu, COVID-19, and other respiratory diseases.

Research

illustration nurse and patient mammogram

Roundup of 3 recent studies on breast cancer screening

New research spotlights overdiagnosis, MRI before surgery, and a new way of predicting breast cancer risk

KPWHRI in the media

Understanding the needs of young cancer survivors

Emergency department use common among AYA cancer survivors

Cure, May 10, 2024

VOICE STUDY

Man sitting at table typing on computer

Understanding young adults’ experiences with cancer

The VOICE study aims to improve the health and health care of people who had cancer as adolescents and young adults.